Related Experiment Video
Updated: Aug 25, 2026

Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
Innate immune sensor NOD2 promotes cartilage degradation and osteoarthritis progression by stabilizing TRAF6 in
Yuting Wang1,2,3, Song Li1, Yonghui Dong4
1Department of Orthopaedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Abstract:
Inflammation driven by the innate immune response plays a crucial role in osteoarthritis (OA) pathogenesis, yet the underlying mechanisms remain incompletely understood. Moreover, current antiinflammatory therapies primarily offer symptomatic relief without altering disease progression. Nucleotide-binding oligomerization domain 2 (NOD2) is an intracellular pattern recognition receptor that detects a broad range of microbial and damage-associated stimuli and has been implicated in several inflammatory conditions. In this study, we investigated the role of NOD2 in OA-associated inflammation and cartilage degradation. Elevated NOD2 expression was observed in both human and mouse osteoarthritic cartilage. Conditional KO of Nod2 in chondrocytes suppressed inflammation-induced catabolic responses in vitro and protected against cartilage degradation in mouse OA models. Mechanistically, we identified tumor necrosis factor receptor-associated factor 6 (TRAF6) as a key downstream mediator through which NOD2 promotes chondrocyte catabolism. Furthermore, we showed that pharmacological inhibition of NOD2 using 2 independent small-molecule inhibitors significantly attenuated OA progression in vivo. Collectively, these findings establish NOD2 as a critical regulator of OA-associated inflammation and cartilage degradation, and they highlight its potential as a therapeutic target for disease-modifying OA treatment.
Insights
Nucleotide-binding oligomerization domain 2 (NOD2) drives osteoarthritis inflammation and cartilage damage. Inhibiting NOD2 shows promise for disease-modifying osteoarthritis treatment.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Inflammation is key in osteoarthritis (OA) pathogenesis, but mechanisms are unclear.
- Current OA therapies offer only symptomatic relief, not disease modification.
- Nucleotide-binding oligomerization domain 2 (NOD2) is an inflammatory pattern recognition receptor.
Purpose of the Study:
- To investigate the role of NOD2 in OA-associated inflammation and cartilage degradation.
- To explore NOD2 as a potential therapeutic target for OA.
Main Methods:
- Assessed NOD2 expression in human and mouse OA cartilage.
- Used conditional knockout of Nod2 in chondrocytes in vitro and in vivo OA models.
- Identified downstream mediators of NOD2 signaling.
- Tested small-molecule NOD2 inhibitors in vivo.
Main Results:
- NOD2 expression was elevated in OA cartilage.
- Chondrocyte-specific Nod2 deletion reduced inflammation and protected cartilage in OA models.
- Tumor necrosis factor receptor-associated factor 6 (TRAF6) was identified as a key mediator.
- NOD2 inhibition significantly attenuated OA progression in vivo.
Conclusions:
- NOD2 is a critical regulator of OA inflammation and cartilage breakdown.
- Targeting NOD2 offers a potential strategy for disease-modifying OA treatment.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
TGF - β Signaling Pathway
Osteoclasts in Bone Remodeling
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...